GleamWall
中文EN

ABVX Abivax S.A. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1956827 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-90.7%
TTM EPS YoY-72.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-135.6%
ROA-85.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets22.1%
Debt / equity0.00x
Current ratio8.75x
Interest coverage-2.15x

Cash quality & payout

Operating cash flow / net income0.48x
Accruals ratio-44.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue——
R&D expense177.76M146.53M
SG&A expense67.67M32.95M
Operating income-246.06M-172.98M
Interest expense111.74M16.99M
Pretax income-330.25M-176.24M
Income tax5.85M0
Net income-336.10M-176.24M
EBITDA-244.98M-171.88M
EPS (basic)-4.83-2.80
EPS (diluted)-4.83-2.80
Weighted avg. shares (diluted)69.53M63.05M
Balance sheet
Cash & equivalents516.68M144.22M
Short-term investments0136,000
Current assets551.24M170.67M
PP&E, netmay include right-of-use assets (IFRS)2.09M2.67M
Goodwill18.42M18.42M
Intangibles6.61M6.61M
Total assets584.34M205.23M
Current liabilities63.02M94.00M
Total liabilities129.14M164.64M
Shareholders' equity455.20M40.58M
Shares outstanding—63.35M
Cash flow statement
Operating cash flow-161.13M-154.07M
Capital expenditure142,000640,000
Free cash flow-161.27M-154.71M
Investing cash flow-8.19M15.76M
Financing cash flow547.31M28.21M
Depreciation & amortization1.07M1.10M
Stock-based compensation35.40M20.22M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.